Search Results for: "Clinic Roundup"
-
Clinic Roundup
Data suggested that the vaccine is well tolerated in humans, and is immunogenic and elicits functional antibodies to H5N1 even at the lowest dose level of 3.75 mcgBioWorld Today | Thursday, October 5, 2006 -
Clinic Roundup
Advanced Life Sciences Holdings Inc., of Woodridge, Ill., said trial data from its lead candidate, cethromycin, a second-generation ketolide antibiotic, demonstrated safety and efficacy at multiple dose levels in community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and anthraxBioWorld Today | Monday, October 2, 2006 -
Clinic Roundup
Patients will receive two dose levels of EVT 201 and placebo, in a random order, for two consecutive nights with a five- to 12-day washout between each periodBioWorld Today | Friday, September 22, 2006 -
Clinic Roundup
The double-blind, randomized, placebo-controlled study will enroll about 500 patients who have undergone segmental colectomy surgery to receive one of two dose levels of methylnaltrexone or placebo following surgery and every six hours until either the patient recovers gastrointestinal function or 10 daysBioWorld Today | Thursday, September 21, 2006 -
Clinic Roundup
Patients in the study received different doses, administered four weeks apart, and results demonstrated that, at each dose level, three injections yielded higher antibody titers than with two injectionsBioWorld Today | Tuesday, August 15, 2006 -
Clinic Roundup
The trial randomized patients to receive either placebo or one of three dose levels three times daily for 12 weeks followed by four weeks without the drugBioWorld Today | Tuesday, July 25, 2006 -
Clinic Roundup
Trigen Holdings AG, of Munich, Germany, said Phase II results of its intravenous direct thrombin inhibitor, TGN 255, showed that a continuous infusion of the drug was well tolerated at all dose levels and a clear dose response regarding coagulation parameters was demonstratedBioWorld Today | Tuesday, July 18, 2006 -
Clinic Roundup
A soluble fusion protein that neutralizes molecules implicated in the pathogenesis of several autoimmune diseases, it appeared to be well tolerated across all dose levels and schedulesBioWorld Today | Tuesday, June 27, 2006 -
Clinic Roundup
Of note, there was an estimated difference of -1.74 percent compared to placebo at the highest dose level of the investigational Type II diabetes treatmentBioWorld Today | Tuesday, June 13, 2006 -
Clinic Roundup
In the analysis, bavituximab showed signs of antiviral activity at all four dose levels, and it also showed evidence of a prolonged antiviral effectBioWorld Today | Thursday, June 8, 2006 -
Clinic Roundup
Data showed the product is well tolerated with no adverse events at all dose levels either alone or associated with potent antigensBioWorld Today | Wednesday, May 31, 2006 -
Clinic Roundup
XP19986 was well tolerated at all dose levels with few reported adverse eventsBioWorld Today | Tuesday, May 23, 2006 -
Clinic Roundup
The agency is concerned that the dose levels of Dimebon used in one of Medivation's rat toxicology studies did not result in sufficient toxicity to define a maximum tolerated doseBioWorld Today | Friday, May 12, 2006 -
Clinic Roundup
In addition to meeting its primary endpoints of safety and tolerability at all dose levels, VEGF Trap showed positive preliminary efficacy results, and the company is starting a Phase II trial in wet AMDBioWorld Today | Wednesday, May 3, 2006 -
Clinic Roundup
Idenix Pharmaceuticals Inc., of Cambridge, Mass., reported that the 200-mg/day dose level of valopicitabine (NM283), combined with pegylated interferon, demonstrated comparable antiviral activity to the 800 mg/day-containing arms in a preliminary analysis of an ongoing Phase IIb trial in treatment-na ve genotype 1 hepatitis C patientsBioWorld Today | Tuesday, May 2, 2006 -
Clinic Roundup
The multicenter, double-blind, placebo-controlled Phase IIa trial randomized patients to receive placebo or one of three dose levels of arimoclomol capsules three times daily for a period of 12 weeksBioWorld Today | Wednesday, April 5, 2006 -
Clinic Roundup
Under the amended protocol, the study now is designated a Phase I/II trial and is more focused, as previously it was testing two dose levels of tgAAC94 in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisBioWorld Today | Friday, March 17, 2006 -
Clinic Roundup
In the ascending, single-dose trial, there were no serious adverse events reported at any of the four dose levels tested, and no potential dose limiting toxicities were observedBioWorld Today | Tuesday, February 28, 2006 -
Clinic Roundup
In addition to meeting the study’s primary endpoint of a linear dose-response for pain relief over four hours as compared to placebo, secondary endpoint results showed statistically superior pain relief compared to placebo for the two highest dose levels of Rylomine and intravenous morphine 7.5 mgBioWorld Today | Friday, February 24, 2006 -
Clinic Roundup
Patients will be treated for two weeks to evaluate the safety and pharmacokinetics of three dose levels of the cortisol synthesis inhibitor, DIO-902BioWorld Today | Thursday, February 23, 2006
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.